Current therapeutic approaches, such as IKKβ inhibitors, target core components of this pathway, and so, although they are potentially capable of abrogating the cancer-promoting activities of NF-κB, they fail to preserve its pleiotropic physiological functions, such as functions in immunity and inflammation (Staudt, 2010, DiDonato et al., 2012). Here, NFKB1 is linked to cancer.